JSLL Jeena Sikho Q3 FY26 results (Oct–Dec 2025) and concall
Jeena Sikho reported a strong Q3 FY26, significantly outperforming previous periods with robust growth in revenue, EBITDA, and PAT. This was driven by increased patient volumes across all service lines and strong traction in Ayurvedic product sales, despite the quarter typically being weak for the healthcare sector. The company is aggressively pursuing product launches, expanding its bed capacity, and focusing on international growth and health insurance penetration to sustain its growth trajectory.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 91.4%, net profit up 415.4% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 114 | 116 | 139 | 174 | 190 +67% | 222 +91% |
| EBITDA | 40 | 30 | 46 | 79 | 92 +130% | 101 +237% |
| Net profit | 27 | 13 | 25 | 51 | 59 +119% | 67 +415% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
